Achondroplasia Research Conference

Category: BioMarin

Achondroplasia
BioMarin

Novel therapy improves height for children with achondroplasia

via Healio/Endocrine Today Children with a common form of skeletal dysplasia saw persistent and sustained improvements in annualized growth... Read More
BioMarin

BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia

SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in... Read More
Achondroplasia
Ascendis
BioMarin
Pfizer
QED

Prospects for Pharmaceutical Treatment of Achondroplasia

John B. Cannon, Ph.D Achondroplasia is a form of dwarfism that occurs about once in every 20,000 births. It... Read More
BioMarin
Hypochondroplasia
Skeletal Dysplasia

Study may change treatment of childhood growth disorders

A child’s growth is often measured by pediatricians during routine physicals to identify abnormalities of growth and stature. An... Read More
Achondroplasia
BioMarin

BioMarin – Update for Achondroplasia Associations

As more cases of COVID-19 are confirmed, we recognize the increased challenges and concerns faced by participants in the... Read More
BioMarin

BioMarin Announced Positive Final Results from Vosoritide Phase 3 pivotal trial. (BMN111-301)

BioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated with Vosoritide Placebo-adjusted Increase... Read More
BioMarin

BioMarin Announces Cumulative Additional Height Gain of 9.0 cm over 54 months versus Natural History in Children with Achondroplasia Treated with Vosoritide in Phase 2 Study

Company Plans to Provide Topline Phase 3 Data by Year End Company Presents Data Confirming that the Phase 3... Read More
BioMarin

BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia

SAN RAFAEL, Calif., June 14, 2018 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company dosed the first participant in... Read More